Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.

Abstract

Background: Therapy for acute lymphoblastic leukemia (ALL) are currently initially efficient, but even if a high percentage of patients have an initial complete remission (CR), most of them relapse. Recent data shows that immunotherapy with either bispecific T-cell engagers (BiTEs) of chimeric antigen receptor (CAR) T cells can eliminate residual chemotherapy-resistant B-ALL cells. Objective: The objective of the manuscript is to present improvements in the clinical outcome for chemotherapy-resistant ALL in the real-life setting, by describing Romania's experience with bispecific antibodies for B-cell ALL. Methods: We present the role of novel therapies for relapsed B-cell ALL, including the drugs under investigation in phase I-III clinical trials, as a potential bridge to transplant. Blinatumomab is presented in a critical review, presenting both the advantages of this drug, as well as its limitations. Results: Bispecific antibodies are discussed, describing the clinical trials that resulted in its approval by the FDA and EMA. The real-life setting for relapsed B-cell ALL is described and we present the patients treated with blinatumomab in Romania. Conclusion: In the current manuscript, we present blinatumomab as a therapeutic alternative in the bridge-to-transplant setting for refractory or relapsed ALL, to gain a better understanding of the available therapies and evidence-based data for these patients in 2019.

• Authors: Dalma Deak, Cristina Pop, Alina-Andreea Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Patric Teodorescu, Angela Dascalescu, Ion Antohe, Bogdan Ionescu, Catalin Constantinescu, Anca Onaciu, Raluca Munteanu, Ioana Berindan-Neagoe, Bobe Petrushev, Cristina Turcas, Sabina Iluta, Cristina Selicean, Mihnea Zdrenghea, Alina Tanase, Catalin Danaila, Anca Colita, Andrei Colita, Delia Dima, Daniel Coriu, Hermann Einsele, Ciprian Tomuleasa
• Journal: Frontiers in immunology (Front Immunol) Vol. 10 Pg. 2856 ( 2019) ISSN: 1664-3224 [Electronic] Switzerland
• PMID: 31921126 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2019 Deak, Pop, Zimta, Jurj, Ghiaur, Pasca, Teodorescu, Dascalescu, Antohe, Ionescu, Constantinescu, Onaciu, Munteanu, Berindan-Neagoe, Petrushev, Turcas, Iluta, Selicean, Zdrenghea, Tanase, Danaila, Colita, Colita, Dima, Coriu, Einsele and Tomuleasa.

Chemical References

• Antibodies, Bispecific
• Antineoplastic Agents, Immunological

Topics

• Antibodies, Bispecific (therapeutic use)
• Antineoplastic Agents, Immunological (therapeutic use)
• Drug Resistance, Neoplasm (drug effects, immunology)
• Humans
• Immunotherapy, Adoptive
• Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (immunology, therapy)